Calaspargase pegol

Product Description

A drug used with other drugs to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. Calaspargase pegol is made up of the enzyme L-asparaginase that is linked to a substance called SC-PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. Calaspargase pegol is a type of protein synthesis inhibitor. Also called Asparlas, EZN-2285, and SC-PEG E. coli L-asparaginase. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/calaspargase-pegol)

Mechanisms of Action: L-Asparagine Converter

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: United States

Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia

Known Adverse Events: Pancreatitis

Company: St. Jude Children's Research Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None